{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:20Z","timestamp":1788262160917,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.leukres.2012.09.013","type":"journal-article","created":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T10:36:04Z","timestamp":1351506964000},"page":"9-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Health-related quality of life in chronic myeloid leukemia"],"prefix":"10.1016","volume":"37","author":[{"given":"Peter C.","family":"Trask","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Reisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Whiteley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.09.013_bib0005","series-title":"Cancer facts and figures 2010","author":"American Cancer Society","year":"2010"},{"issue":"Suppl. 5","key":"10.1016\/j.leukres.2012.09.013_bib0010","doi-asserted-by":"crossref","first-page":"v165","DOI":"10.1093\/annonc\/mdq201","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Baccarani","year":"2010","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.leukres.2012.09.013_bib0015","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.09.013_bib0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.leukres.2012.09.013_bib0025","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome \u2013 positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.09.013_bib0030","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome \u2013 positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.leukres.2012.09.013_bib0035","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.013_bib0040","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.leukres.2012.09.013_bib0045","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2008.03.017","article-title":"Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials \u2013 a systematic review to evaluate the added value in supporting clinical decision making","volume":"44","author":"Efficace","year":"2008","journal-title":"Eur J Cancer"},{"issue":"March","key":"10.1016\/j.leukres.2012.09.013_bib0050","article-title":"Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes","author":"Efficace","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.leukres.2012.09.013_bib0055","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study","volume":"21","author":"Hahn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.09.013_bib0060","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0163278705275341","article-title":"General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G)","volume":"28","author":"Brucker","year":"2005","journal-title":"Eval Health Prof"},{"key":"10.1016\/j.leukres.2012.09.013_bib0065","doi-asserted-by":"crossref","first-page":"A282","DOI":"10.1016\/S1098-3015(10)74385-0","article-title":"Using the FACT-Leukemia subscale to evaluate quality of life in leukemia patients worldwide","volume":"12","author":"Arnold","year":"2009","journal-title":"Value Health"},{"issue":"July","key":"10.1016\/j.leukres.2012.09.013_bib0070","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.09.013_bib0075","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Turkina A, et al. Safety and efficacy of second-line bosutinib (SKI-606) in imatinib-resistant or -intolerant chronic phase (CP) chronic myeloid leukemia (CML). Paper presented at 15th Congress of the European Hematology Association, Barcelona, Spain, June 10\u201313; 2010."},{"key":"10.1016\/j.leukres.2012.09.013_bib0080","doi-asserted-by":"crossref","unstructured":"Gambacorti-Passerini C, Kim DW, Kantarjian HM, et al. An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Paper presented at 52nd American Society of Hematology Annual Meeting and Exposition, Orlando, FL, December 4\u20137; 2010.","DOI":"10.1182\/blood.V116.21.208.208"},{"key":"10.1016\/j.leukres.2012.09.013_bib0085","series-title":"Center on Outcomes, Research and Education, Evanston Northwestern Healthcare and Northwestern University","article-title":"The manual of the functional assessment of chronic illness therapy (FACIT) measurement system","author":"Cella","year":"1997"},{"issue":"3","key":"10.1016\/j.leukres.2012.09.013_bib0090","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.09.013_bib0095","unstructured":"Cella D, Webster K, Beaumont J, Du H, Lai J-S, Rosen S, et al. Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) Questionnaire, Value in Health, in press."},{"key":"10.1016\/j.leukres.2012.09.013_bib0100","series-title":"SAS 9.2","year":"2008"},{"key":"10.1016\/j.leukres.2012.09.013_bib0105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","article-title":"Natural history and staging of chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612003864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612003864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:57:58Z","timestamp":1758934678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612003864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0145212612003864"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.09.013","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2012.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}